Horizon SPAC II and SL Bio Announce Nasdaq Business Combination

New York, NY, May 12, 2025 – Horizon Space Acquisition II Corp. (HSPT), a special purpose acquisition company, and SL Bio Ltd., a clinical-stage biomedical company, have entered into a definitive business combination agreement. Upon completion, SL Science Holding Limited will be listed on Nasdaq.

SL Bio focuses on cancer treatment and regenerative medicine through cellular and gene therapy technologies, including immunotherapies like Armed-T and Gamma Delta T (GDT) cell technologies. Their pipeline targets blood cancers, pancreatic cancer, and brain cancer. Additionally, SL Bio is advancing the use of cow milk-derived exosomes and tangerine extract in regenerative applications for skin and hair care.

... Read on — Members only